Market research
RAC.AU Race Oncology Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 396M
- P/E ratio
- Not available
- Analyst target
- 7.46
- Dividend yield
- Not available
- Beta
- 0.83
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000RAC3
- Market cap
- 396M
- P/E ratio
- Not available
- Analyst target
- 7.46
- Dividend yield
- Not available
- Beta
- 0.83
About
About Race Oncology Limited
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RAC.AU discussion.
5 years, 5 months ago
Race Oncology Limited is currently in a long term uptrend where the price is trading 39.3% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Race Oncology Limited's total revenue rose by 273.9% to $11K since the same quarter in the previous year.
Its net income has dropped by 37.1% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 39.0% to $-592K since the same quarter in the previous year.
Based on the above factors, Race Oncology Limited gets an overall score of 3/5.